EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial

Hongjun Song, Chentian Shen, Youben Fan, Zhiyan Liu iD, Yonggang Wang, Quanyong Luo iD, Libo Chen iD

The Oncologist · 05.11.2026 · 31 (12)

DOI: 10.1093/oncolo/oyag426 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 22.10.2026. Verfasst von Hongjun Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Sh…. Hauptthemen laut MEDLINE: Indoles, Quinolines, Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radioiodine (RAI) alone exhibited limited efficacy in distant metastatic differentiated thyroid cancer (DTC). We hypothesized that pretreatment with anlotinib, a potent antiangiogenic tyrosine kinase inhibitor, would reduce tumor burden and improve therapeutic response.

Methods

This prospective, single-arm phase II trial enrolled patients with measurable distant metastatic DTC. All patients received anlotinib 12 mg/day orally for 12 weeks. After confirmation of RAI-avid target lesions on diagnostic 131I-WBS, patients were treated with 7.4 GBq RAI and followed up for another 12 weeks. Sequential therapy continued until no effect of RAI could be anticipated. Primary endpoints were objective response rate (ORR) and safety. Registered with the Chinese Clinical Trial Registry (ChiCTR2100045178; https://www.chictr.org.cn).

Results

24 patients were enrolled. 14 (58%) were excluded due to non-RAI-avid target lesions; 10 (42%) with RAI-avid lesions received sequential therapy (median, 4.5 cycles). ORR was 60% (all partial responses), disease control rate 100%. With median follow-up 34.5 months, no disease progression or death occurred. In the subgroup of 8 patients with bone target lesions, ORR was 50%. Grade 3 anlotinib-related adverse events occurred in 30% of patients; no grade 4/5 toxicities or grade ≥2 RAI-related events were observed.

Conclusion

Sequential anlotinib followed by RAI therapy demonstrated promising antitumor activity (ORR 60%) and favorable safety in RAI-avid distant metastatic DTC, particularly in bone metastases. These findings are hypothesis-generating and require validation in a randomized trial with an RAI monotherapy control arm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesQuinolinesThyroid NeoplasmsIodine RadioisotopesHumansFemaleMaleMiddle AgedAdultNeoplasm MetastasisAgedProspective Studies

Stichwörter der Autor:innen

anlotinibdifferentiated thyroid carcinomametastasisradioiodinetyrosine kinase inhibitor

Substanzen

anlotinibIndolesQuinolinesIodine Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China.
  • Department of Surgery, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China.
  • Department of Pathology, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China.
  • Department of Oncology, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China.

ORCID-Profile: Zhiyan Liu, Quanyong Luo, Libo Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Song, H., Shen, C., Fan, Y., Liu, Z., Wang, Y., Luo, Q., & Chen, L. (2026). Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial. The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag426

Vancouver

Song H, Shen C, Fan Y, Liu Z, Wang Y, Luo Q, et al. Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial. The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag426

BibTeX
@article{Song2026,
  author = {Song, Hongjun and Shen, Chentian and Fan, Youben and Liu, Zhiyan and Wang, Yonggang and Luo, Quanyong and Chen, Libo},
  title = {Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {12},
  doi = {10.1093/oncolo/oyag426}
}
Kostenlos starten →